5,326 new cases of coronavirus infection have been reported in India, the lowest in 581 days, taking the total number of COVID-19 cases to 3,47,52,164, while the active cases declined to 79,097, the lowest in 574 days. Is.
you can track coronavirus Cases, deaths and testing rates at the national and state levels Here, a list of state helpline number also available.
Here are the updates:
National
Two hundred micron cases reported in India so far, 5,326 new COVID-19 cases
The Union Health Ministry on December 21 said that so far two hundred cases of omicron type coronavirus have been detected in India, out of which 77 patients have been cured or migrated. Maharashtra and Delhi have reported 54 cases of the Omicron variant, while Telangana has reported 20 cases. cases, Karnataka 19, Rajasthan 18, Kerala 15 and Gujarat 14 cases.
The ministry’s data updated on Tuesday also said that India recorded 5,326 new cases of coronavirus infection, the lowest in 581 days, taking the total number of COVID-19 cases to 3,47. ,52,164, while active cases declined to 79,097, the lowest in 574 days.
Orissa
Omicron’s first cases reported in Odisha
Ajay Parida, director of the Institute of Life Science, Bhubaneswar, said that two foreign returnees have been found infected with the Omicron variant after genomic sequencing of their samples. These are the first cases of Omicron reported in Odisha. truth beautiful detail
America
Omicron becomes dominant form in US
Federal health officials said Monday that Omicron has overtaken other types and is now the dominant version of the coronavirus in the US, accounting for 73% of new infections last week.
Numbers from the Centers for Disease Control and Prevention showed a nearly six-fold increase in Omicron’s share of infections in just one week.
In most of the country, it is even higher.
New Zealand
New Zealand delays plans to reopen border over Omicron concerns
New Zealand on Tuesday postponed its phased border reopening plans until the end of February, citing the rapid global spread of the Omicron version of the coronavirus.
The South Pacific nation began easing some of the world’s toughest pandemic measures and was to progressively loosen its international border restrictions from January, with all foreign tourists allowed into the country from April.
Non-quarantine travel, which was to be opened to New Zealanders in Australia from January 16, will be pushed back to the end of February, COVID-19 response minister Chris Hipkins said at a news conference in Wellington.
“All the evidence so far points to Omicron to be the most transmissible COVID-19 variant ever.
America
US records first death, believed to be related to Omicron variant
Health officials in Texas said the state recorded the first death related to the Omicron COVID-19 variant, ABC News Reported on Monday.
It is believed to be the first known recorded Omicron death in the United States. abc Citing Harris County health officials, said in its report.
The report said the victim was a man in his 50s who had not been vaccinated and had underlying health conditions. Reuters
Geneva
Spreading and infecting Omicron vaccines – WHO
The head of the World Health Organization (WHO) said on Monday that the omicron version of the coronavirus is spreading faster than the delta version and can cause infections among people who have already been vaccinated or have recovered from the COVID-19 disease. is generating.
“There is now consistent evidence that Omicron is spreading much faster than the delta version,” WHO Director-General Tedros Adhanom Ghebreyesus told a news briefing for journalists in Geneva, held at its new headquarters building.
“And it is more likely that people who have been vaccinated or recovered from COVID-19 can become infected or re-infected,” Mr. Tedros said. Reuters
National
Report in a week on effectiveness of vaccine against Omicron: Union Health Minister
Union Health Minister Mansukh Mandaviya told the Rajya Sabha on Monday that a report on the effectiveness of vaccines available in the country against the Omicron variant of COVID-19 would be available in a week.
He made the observation while responding to “a short duration discussion on the situation arising out of the Omicron variant of the COVID-19 virus in the country”.
The EU approved the 5th COVID-19 vaccine for the bloc, a Novavax . By
The European Union’s drug regulator on Monday granted a fifth COVID-19 vaccine for use in a bloc of 27 countries, granting conditional marketing authorization to a two-dose vaccine made by US biotech company Novavax.
The European Medicines Agency has decided to recommend a conditional marketing authorization for the vaccine for people 18 years of age and older, which must be ratified by the EU’s Executive Commission, as several European countries grapple with an increase in infections. And amid concerns about the spread of the new. Omicron Edition.
Novavax says it’s currently testing how its shots stack up against the Omicron version, and like other manufacturers has begun producing an updated version to better match that version, if eventually. need it. AP
Geneva
WEF postpones Davos annual meeting 2022 due to Omicron outbreak
The World Economic Forum said on Monday it has decided to postpone its annual meeting in the Swiss alpine ski resort city of Davos to 2022 in light of the continuing uncertainty over the Omicron outbreak.
The annual meeting, which was due to take place in Davos-Klosters, Switzerland, between January 17-21, 2022, is now planned for the start of summer.
In a statement on the postponement of the 2022 meeting to early summer, the WEF said the participating ‘State of the World’ will bring together global leaders to focus on shaping solutions to the world’s biggest challenges. Will feature in a headline series of sessions.
“The current pandemic situation makes it extremely difficult to have a global meeting in person. Preparation has been guided by expert advice and benefits from the close cooperation of the Swiss government at all levels.” PTI
National
Bharat Biotech seeks DCGI’s nod for phase-3 study of intra-nasal covid vaccine as a booster dose
Bharat Biotech has received approval from India’s drug regulator to conduct a phase-3 study for its intra-nasal COVID-19 vaccine as a booster dose on participants who have received the Kovashield or Covaxin vaccine, official sources said on Monday. has asked.
India has not yet approved the use of the intranasal vaccine BBV154 developed by the Hyderabad-based company.
The company had received the approval of the Drug Controller General of India (DCGI) for the Phase II clinical trial of the nasal vaccine in August.
The company reports that doses of the vaccine administered to healthy volunteers in phase-1 clinical trials have been well tolerated. No serious adverse event was reported, the DBT had said. PTI
,